# Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer

> **NCT00258284** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT00258284
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2007-11
- **Final completion:** 2007-11
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-03-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00258284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00258284, "Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00258284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*